AU2019365654B2 - Cleavable activators of CXCR3 and methods of use - Google Patents

Cleavable activators of CXCR3 and methods of use Download PDF

Info

Publication number
AU2019365654B2
AU2019365654B2 AU2019365654A AU2019365654A AU2019365654B2 AU 2019365654 B2 AU2019365654 B2 AU 2019365654B2 AU 2019365654 A AU2019365654 A AU 2019365654A AU 2019365654 A AU2019365654 A AU 2019365654A AU 2019365654 B2 AU2019365654 B2 AU 2019365654B2
Authority
AU
Australia
Prior art keywords
peptide
cxcl
amino acid
recombinant
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019365654A
Other languages
English (en)
Other versions
AU2019365654A1 (en
AU2019365654A8 (en
Inventor
Alan H. Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU2019365654A1 publication Critical patent/AU2019365654A1/en
Publication of AU2019365654A8 publication Critical patent/AU2019365654A8/en
Application granted granted Critical
Publication of AU2019365654B2 publication Critical patent/AU2019365654B2/en
Priority to AU2025200880A priority Critical patent/AU2025200880A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2019365654A 2018-10-22 2019-10-18 Cleavable activators of CXCR3 and methods of use Active AU2019365654B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200880A AU2025200880A1 (en) 2018-10-22 2025-02-08 Cleavable activators of CXCR3 and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748711P 2018-10-22 2018-10-22
US62/748,711 2018-10-22
PCT/US2019/056955 WO2020086400A1 (en) 2018-10-22 2019-10-18 Cleavable activators of cxcr3 and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200880A Division AU2025200880A1 (en) 2018-10-22 2025-02-08 Cleavable activators of CXCR3 and methods of use

Publications (3)

Publication Number Publication Date
AU2019365654A1 AU2019365654A1 (en) 2021-05-13
AU2019365654A8 AU2019365654A8 (en) 2021-05-20
AU2019365654B2 true AU2019365654B2 (en) 2024-11-14

Family

ID=70330587

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019365654A Active AU2019365654B2 (en) 2018-10-22 2019-10-18 Cleavable activators of CXCR3 and methods of use
AU2025200880A Pending AU2025200880A1 (en) 2018-10-22 2025-02-08 Cleavable activators of CXCR3 and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200880A Pending AU2025200880A1 (en) 2018-10-22 2025-02-08 Cleavable activators of CXCR3 and methods of use

Country Status (12)

Country Link
US (2) US12110316B2 (enExample)
EP (1) EP3870212A4 (enExample)
JP (3) JP7426121B2 (enExample)
KR (1) KR20210081372A (enExample)
CN (2) CN120022352A (enExample)
AU (2) AU2019365654B2 (enExample)
BR (1) BR112021007414A2 (enExample)
CA (1) CA3116325A1 (enExample)
IL (2) IL324815A (enExample)
MX (1) MX2021004496A (enExample)
SG (1) SG11202103497WA (enExample)
WO (1) WO2020086400A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210081372A (ko) * 2018-10-22 2021-07-01 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 절단 가능한 cxcr3의 활성제 및 이의 사용 방법
GB202208950D0 (en) * 2022-06-17 2022-08-10 Ucl Business Ltd Treatment of the corneal endothelium
WO2024118744A2 (en) * 2022-11-30 2024-06-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Coacervate formulations of cxcr3-activating peptides for controlled release in ophthalmic and topical treatments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
MXPA00003885A (es) 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20070116669A1 (en) * 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
GB2377444A (en) 2001-04-09 2003-01-15 Smithkline Beecham Plc Chemokine-family polypeptide
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
US9180167B2 (en) 2011-08-26 2015-11-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Activators of CXCR3 for the treatment of angiopathies of the eye
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
AU2014306074B2 (en) * 2013-08-05 2018-08-30 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
US9895419B2 (en) * 2014-01-21 2018-02-20 University of Pittsburgh—of the Commonwealth System of Higher Education Goblet cell replacement therapy
ES2738582T3 (es) * 2014-02-14 2020-01-23 Immune Design Corp Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20210081372A (ko) 2018-10-22 2021-07-01 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 절단 가능한 cxcr3의 활성제 및 이의 사용 방법

Also Published As

Publication number Publication date
EP3870212A1 (en) 2021-09-01
SG11202103497WA (en) 2021-05-28
JP2022512770A (ja) 2022-02-07
US20250002549A1 (en) 2025-01-02
BR112021007414A2 (pt) 2021-08-10
US20210388048A1 (en) 2021-12-16
JP2025172140A (ja) 2025-11-20
IL282431A (en) 2021-06-30
EP3870212A4 (en) 2022-11-16
AU2019365654A1 (en) 2021-05-13
JP7798368B2 (ja) 2026-01-14
CN113038965A (zh) 2021-06-25
IL324815A (en) 2026-01-01
IL282431B2 (en) 2026-04-01
AU2019365654A8 (en) 2021-05-20
WO2020086400A1 (en) 2020-04-30
CN120022352A (zh) 2025-05-23
US12110316B2 (en) 2024-10-08
KR20210081372A (ko) 2021-07-01
JP2024009210A (ja) 2024-01-19
CN113038965B (zh) 2025-02-07
JP7426121B2 (ja) 2024-02-01
AU2025200880A1 (en) 2025-03-06
IL282431B1 (en) 2025-12-01
MX2021004496A (es) 2021-06-04
CA3116325A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US20250002549A1 (en) Cleavable activators of cxcr3 and methods of use
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
AU2014254019B2 (en) Methods of using interleukin-10 for treating diseases and disorders
JP6124943B2 (ja) Ｓａｐ変異体及びその使用
JP6675394B2 (ja) 疾患及び障害の治療のためにインターロイキン−１０を使用する方法
HK1042434B (zh) 干扰素-β-1A的聚合物缀合物及其使用
JP2026002845A (ja) 眼の感染症および疾患を処置するための組成物および方法
CN106573072A (zh) 降低血清胆固醇的方法
JP2012530714A5 (enExample)
CA2746976A1 (en) Modulators of the cx3cr1 receptor and therapeutic uses thereof
EP2753691A1 (en) Novel mutated tissue plasminogen activators and uses thereof
JP7455457B2 (ja) 筋萎縮性側索硬化症を治療するための方法と薬剤
SK287523B6 (sk) Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby
JP2009513689A (ja) 神経学的疾患の治療、及び／又は予防のためのｓｄｆ−１の使用
KR20230005298A (ko) 척수성 근위축증의 치료 방법 및 약물
CN111905103A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
HK40123732A (zh) Cxcr3的可切割激活剂及其使用方法
HK40055610A (en) Cleavable activator of cxcr3 and use method thereof
HK40055610B (zh) Cxcr3的可切割激活剂及其使用方法

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 19 , PAGE(S) 4117 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, APPLICATION NO. 2019365654, UNDER INID (54) CORRECT THE TITLE TO READ CLEAVABLE ACTIVATORS OF CXCR3 AND METHODS OF USE

FGA Letters patent sealed or granted (standard patent)